| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
PKA I PKA II PDE3A 47.6 μM (Ki) PDE10 GAF domain 50 μM (EC50)
Sp-cAMPS sodium salt targets two major components of the cAMP signaling pathway: protein kinase A (PKA) and phosphodiesterase 3A (PDE3A). As a cAMP analog, Sp-cAMPS binds to the regulatory subunits of PKA I and PKA II, causing dissociation of the catalytic subunits and activation of kinase activity. Additionally, Sp-cAMPS inhibits PDE3A, the enzyme responsible for hydrolyzing cAMP to AMP. By both activating PKA and inhibiting cAMP degradation, Sp-cAMPS potentiates cAMP signaling. The compound is a "Sp" diastereomer, which refers to the stereochemistry at the phosphorus atom of the cyclic phosphate. |
|---|---|
| ln Vitro |
The irritating diastereomer of adenosine cyclic 3',5'-phosphorothioate, or Sp-cAMPS sodium salt, stimulates hepatocytes in a manner similar to that induced by glucagon. The rise in Ca2+ levels induced by glucagon can be mimicked by the sodium salt Sp-cAMPS [4].
In vitro studies have demonstrated that Sp-cAMPS sodium salt is a potent activator of PKA I and PKA II, with activity comparable to cAMP itself. The compound also inhibits PDE3A with a Ki of 47.6 μM. Unlike cAMP, Sp-cAMPS is resistant to hydrolysis by phosphodiesterases, providing sustained activation of PKA in cellular assays. The compound has been used extensively to study cAMP-dependent signaling pathways, including regulation of glycogen metabolism, lipolysis, and gene expression. Sp-cAMPS is a standard tool compound for investigating the roles of PKA and cAMP in various cellular processes. |
| ln Vivo |
Direct injection of Sp-cAMPS (1 µg/µL) sodium salt into the prefrontal cortex of chronic alcohol consumption (CAC) mice either dramatically improved the working memory performance of withdrawn animals or negatively impacted the performance of aquatic animals [5].
In vivo activity data for Sp-cAMPS sodium salt is limited, as the compound is primarily used as a research tool in biochemical and cellular studies. The compound's resistance to phosphodiesterase hydrolysis suggests it could have prolonged activity in vivo compared to cAMP. However, comprehensive in vivo studies have not been extensively reported. The compound is typically used to study cAMP signaling in isolated tissues or cell culture systems, where its effects on PKA activation and PDE inhibition can be precisely controlled. |
| Enzyme Assay |
Cell-free biochemical assays for Sp-cAMPS typically measure PKA activation or PDE inhibition. For PKA activation assays, a standard protocol involves incubating purified PKA holoenzyme with varying concentrations of Sp-cAMPS (0.01-100 μM) and a peptide substrate (e.g., Kemptide) with [γ-³²P]ATP in kinase buffer at 30°C. PKA activity is measured by incorporation of ³²P into the substrate. For PDE inhibition assays, purified PDE3A is incubated with varying concentrations of Sp-cAMPS and a cAMP substrate, and cAMP hydrolysis is measured using a colorimetric or radiometric method. Ki values are determined from dose-response curves using nonlinear regression analysis.
|
| Cell Assay |
Cellular assays for Sp-cAMPS sodium salt typically use cell lines expressing PKA and PDE3A to assess activation of cAMP signaling. A standard protocol involves culturing cells in 96-well plates, treating with Sp-cAMPS at concentrations ranging from 1-100 μM for 1-24 hours, and measuring downstream effects. To facilitate cell entry, Sp-cAMPS may be used with membrane-permeabilizing agents or delivered via microinjection. PKA activation is assessed by measuring phosphorylation of PKA substrates (e.g., CREB) using Western blotting with phospho-specific antibodies. cAMP levels can be measured by ELISA. Gene expression changes are assessed by qPCR for CREB target genes.
|
| Animal Protocol |
In vivo studies with Sp-cAMPS sodium salt are limited, as the compound is primarily a research tool for in vitro applications. If administered systemically, the compound's charged nature (sodium salt) would limit cell permeability, requiring specialized delivery methods. Studies typically use isolated tissue preparations or cell culture systems rather than whole animal models. For tissue studies, tissues are incubated with Sp-cAMPS in organ baths or culture media, and physiological responses are measured. The compound's effects on smooth muscle relaxation, cardiac contractility, or other cAMP-dependent processes can be assessed in these systems.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Sp-cAMPS sodium salt is limited, as the compound is primarily used in research settings. The compound's charged nature (sodium salt of a cyclic phosphate) limits cell membrane permeability compared to uncharged molecules. The molecular weight is 367.25 g/mol. For in vivo applications, the compound would likely require formulation to enhance bioavailability. The compound is typically dissolved in water or buffer for in vitro studies. Metabolism would involve dephosphorylation or other degradation pathways.
|
| Toxicity/Toxicokinetics |
Toxicological data specific to Sp-cAMPS sodium salt is limited, as the compound is a research chemical used primarily in in vitro settings. At effective concentrations (micromolar range for PKA activation), the compound does not show significant cytotoxicity in most cell types. Higher concentrations may have effects due to sustained PKA activation. The compound's resistance to PDE hydrolysis means it can produce prolonged cAMP signaling, which could have biological effects beyond those of physiological cAMP. Standard laboratory safety precautions should be observed when handling this compound.
|
| References | |
| Additional Infomation |
Sp-cAMPS sodium salt is a research compound and not an approved drug. No clinical trials or regulatory approvals exist for this compound. It is commercially available from various suppliers for research use only. The compound's primary value lies in its utility as a pharmacological tool for studying cAMP-dependent signaling pathways. As a membrane-permeant, PDE-resistant cAMP analog, Sp-cAMPS enables researchers to activate PKA and study downstream effects in cells and tissues. Its dual mechanism of action (PKA activation and PDE inhibition) makes it a unique tool for investigating the roles of cAMP in various physiological and pathological processes.
|
| Molecular Formula |
C10H11N5NAO5PS
|
|---|---|
| Molecular Weight |
367.25
|
| Exact Mass |
367.011
|
| CAS # |
142439-95-0
|
| Related CAS # |
Rp-cAMPS triethylammonium salt;151837-09-1;Rp-cAMPS sodium salt;142439-94-9;Rp-cAMPS;73208-40-9;Sp-cAMPS;71774-13-5;Sp-cAMPS triethylamine;93602-66-5
|
| PubChem CID |
23682235
|
| Appearance |
White to off-white solid powder
|
| LogP |
0.969
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
23
|
| Complexity |
508
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C(N=CN=C43)N)O)OP(=S)(O1)[O-].[Na+]
|
| InChi Key |
YTUKZYORDGLGPR-NVGWRVNNSA-M
|
| InChi Code |
InChI=1S/C10H12N5O5PS.Na/c11-8-5-9(13-2-12-8)15(3-14-5)10-6(16)7-4(19-10)1-18-21(17,22)20-7;/h2-4,6-7,10,16H,1H2,(H,17,22)(H2,11,12,13);/q;+1/p-1/t4-,6-,7-,10-,21?;/m1./s1
|
| Chemical Name |
sodium;(4aR,6R,7R,7aS)-6-(6-aminopurin-9-yl)-2-oxido-2-sulfanylidene-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (272.29 mM)
H2O: 86.67 mg/mL (236.00 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.81 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.81 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.81 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 50 mg/mL (136.15 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7229 mL | 13.6147 mL | 27.2294 mL | |
| 5 mM | 0.5446 mL | 2.7229 mL | 5.4459 mL | |
| 10 mM | 0.2723 mL | 1.3615 mL | 2.7229 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
